Sign up USA
Proactive Investors - Run By Investors For Investors
Markets

CryptoCann™ Report: Ivy League schools investing in crypto funds; MedMen scoops up more cannabis licenses via PharmaCann acquisition

Yale, Harvard, Stanford, Dartmouth, MIT and UNC have reportedly invested in crypto funds

The Crypto Report

Ivy League schools have churned out multiple presidents, Fortune 500 CEOs and other notable alumni and many have the multi-billion endowments to show for it.

Yale University recently announced some of its $30 billion endowment would be put into the cryptocurrency market via an investment in crypto fund Paradigm.

READ: Xinyuan Real Estate is building a global real estate ̶ and blockchain ̶ empire

Other prestigious universities have been betting on crypto as well. 

Harvard University, Stanford University, Dartmouth College, Massachusetts Institute of Technology and the University of North Carolina have invested into at least one cryptocurrency fund, according to a report by The Information.

Endowments taking baby steps into the cryptocurrency market may signal a shift in investor sentiment.

In blockchain news, BMW is hosting a tournament for blockchain applications in vehicles, as per a Coin Telegraph report.

The MOBI Grand Challenge will be a three-year-long event beginning October 12, awarding winners more than $1 million worth of tokens.

The first fourth-month challenge is looking for “potential uses of blockchain in coordinating vehicle movement and improving transportation in urban environments.”

The champions of the first challenge will be granted $350,000 worth of awards and may have their technology featured at an event hosted by BMW Group in Munich, Germany in February 2019.

The Cann Report

MedMen Enterprises Inc (CSE:MMEN,OTCQB:MMNFF) is expanding its reach via its latest $682 million acquisition of medical cannabis company PharmaCann LLC.

Its portfolio will now include cannabis licenses in 12 states, adding licenses in Illinois, New York, Pennsylvania, Maryland, Massachusetts, Ohio, Virginia and Michigan. The company is permitted to operate a total of 79 cannabis facilities.

READ: Biome Grow starts trading on Canadian Securities Exchange; aims to build Canadian cannabis conglomerate

“This would not have been possible even two years ago and is a testament to how far both the industry and these two companies have evolved,” said CEO Adam Bierman in the company’s press release.

MedMen currently operates 14 retail stores in California, Nevada and New York.

Cannabis retailers sell all kinds of cannabis strains, offering dessert flavors like key lime pie and lemon meringue or flavors named after celebrities like Snoop Dogg and Tommy Chong.

However, the strains may not be so different after all, according to research from the University of British Columbia’s Okanagan campus.

"It is estimated that there are several hundred or perhaps thousands of strains of cannabis currently being cultivated," said UBC chemistry professor Susan Murch in an interview with science publication Phys.org "We wanted to know how different they truly are, given the variety of unique and exotic names."

The research shows that while breeding highly potent strains of cannabis impacts the genetic diversity within the crop, the THC and CBD levels were not affected.

Join our Crypto, Blockchain and Cannabis Telegram group here
MedMen storefront
MedMen acquired medical cannabis producer PharmaCann in a $682 million stock deal

No investment advice

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is suitable or advisable for any specific person. You understand that the Company receives either monetary or securities compensation for our services. We stand to benefit from any volume this write-up may generate.

You further understand that none of the information providers or their affiliates will advise you personally concerning the nature, potential, advisability, value or suitability of any particular security, portfolio of securities, transaction, investment strategy, or other matter.

You understand that the Site may contain opinions from time to time with regard to securities mentioned in other products, including company related products, and that those opinions may be different from those obtained by using another product related to the Company. You understand and agree that contributors may write about securities in which they or their firms have a position, and that they may trade such securities for their own account. In cases where the position is held at the time of publication and such position is known to the Company, appropriate disclosure is made. However, you understand and agree that at the time of any transaction that you make, one or more contributors may have a position in the securities written about. You understand that price and other data is supplied by sources believed to be reliable, that the calculations herein are made using such data, and that neither such data nor such calculations are guaranteed by these sources, the Company, the information providers or any other person or entity, and may not be complete or accurate.

From time to time, reference may be made in our marketing materials to prior articles and opinions we have published. These references may be selective, may reference only a portion of an article or recommendation, and are likely not to be current. As markets change continuously, previously published information and data may not be current and should not be relied upon.

Copyright © Proactiveinvestors.com, 2018. All Rights Reserved - Proactive Investors North America Inc., Proactive Investors LLC

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use